Evidence map›Paper›PMID 29021129›Full record

ArticleJMIR research protocols2017

Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.

Lisa M Hess, David M Kern, Gebra Cuyun Carter, Katherine Winfree, Liya Wang, Angelina Sontag, Ana B Oton

Abstract read
In one paragraph

Article in JMIR research protocols, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lisa M HessEli Lilly and Company, Indianapolis, IN, United States.ORCID http://orcid.org/0000-0003-3631-3941
David M KernHealthCore, Inc, Wilmington, DE, United States.ORCID http://orcid.org/0000-0001-5417-3925
Gebra Cuyun CarterEli Lilly and Company, Indianapolis, IN, United States.ORCID http://orcid.org/0000-0002-6549-0069
Katherine WinfreeEli Lilly and Company, Indianapolis, IN, United States.ORCID http://orcid.org/0000-0003-2088-1004
Liya WangHealthCore, Inc, Wilmington, DE, United States.ORCID http://orcid.org/0000-0003-0317-5685
Angelina SontagEli Lilly and Company, Indianapolis, IN, United States.ORCID http://orcid.org/0000-0003-4012-4537
Ana B OtonEli Lilly and Company, Indianapolis, IN, United States.ORCID http://orcid.org/0000-0002-6126-7353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival outcomes are related to treatment choices in a line of therapy and to treatment sequences across all lines of therapy.

objectiveThe Real-World Treatment Sequences and Outcomes among Patients with NSCLC (RESOUNDS) study is designed to (1) evaluate treatment sequences used for patients who receive at least two lines of therapy for non-small cell lung cancer (NSCLC) in the United States and (2) evaluate patient outcomes in terms of progression-free and overall survival related to treatment sequencing. Additional objectives include the evaluation of symptoms, comorbidities, and health care resource utilization and costs.

methodsPatients will be censored at loss to follow-up due to leaving the health plan or reaching the end of the study period.

resultsThis study is ongoing.

conclusionsThe RESOUNDS cohort study is a novel approach to building a comprehensive dataset that mimics a prospective observational study using linked patient-level data from four real-world data sources. This study will provide timely information on the sequencing of treatments for patients with NSCLC.

Indexed as

cancerchemotherapyline of therapynon-small cell lung canceroverall survivalprogression-free survivalreal-world dataregimentreatment sequence

Identifiers

PMID29021129
PMCPMC5658639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.